Novel GCN2 Modulator HC-7366 Inhibits Myeloid-derived Suppressor Cells and Reduces Pulmonary Metastases SITC 2022 GCN2 Poster 1327_J_Drees PDF
Perk Inhibitor HC-5404 Demonstrates Immune-activation and Anti-tumor Efficacy in Combination with Anti-PD1 Immune Checkpoint Inhibitor Antibody SITC 2022 PERK Poster_P884 Chan PDF
Cancer immunotherapy via myeloid signaling pathway co-activation (Wattenberg et al. AACR Pancreatic Cancer 2022)
Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)
Association of immunopharmacodynamic responses of Imprime PGG plus pembrolizumab with clinical benefit in metastatic triple negative breast cancer (TNBC) subjects failing front-line chemotherapy
Clinical benefit evident with early immunopharmacodynamic responses in prior checkpoint failed metastatic melanoma patients treated with Imprime PGG and pembrolizumab
Imprime (β-1,3/1,6 glucan) synergizes with a CD40 agonist to stimulate T cell-dependent antitumor activity in a poorly immunogenic model of pancreatic carcinoma
Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth in vivo
Imprime PGG, a soluble yeast β-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing